InvestorsHub Logo
Followers 8
Posts 1924
Boards Moderated 0
Alias Born 09/10/2012

Re: None

Monday, 11/22/2021 6:38:54 AM

Monday, November 22, 2021 6:38:54 AM

Post# of 408
BLUEBIRD BIO ANNOUNCES FDA PRIORITY REVIEW OF BIOLOGICS LICENSE APPLICATION FOR BETI-CEL GENE THERAPY
BLUEBIRD BIO INC - FDA SET PDUFA DATE OF MAY 20, 2022

“The FDA’s acceptance of our BLA for beti-cel brings us one step closer to potentially providing a one-time treatment that can address the underlying cause of ß-thalassemia and offer patients freedom from regular transfusions,” said Andrew Obenshain

Additional data through August 2021 will be presented at the 63(rd) American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News